The shared tumor associated antigen cyclin-A2 is recognized by high-avidity T-cells

Eisei Kondo, Britta Maecker, Andreas Draube, Nela Klein-Gonzalez, Alexander Shimabukuro-Vornhagen, Joachim L. Schultze, Michael S. Von Bergwelt-Baildon

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Cyclin-A2, a key cell cycle regulator, has been shown to be overexpressed in various types of malignancies with little expression in normal tissue. Such tumor-associated genes potentially are useful targets for cancer immunotherapy. However, high-avidity cyclin-specific T cells are considered to be thymically deleted. We identified at least one nonameric HLA-A*0201 binding cyclin-A2 epitope by a reverse immunology approach. Using a highly efficient T-cell expansion system that is based on CD40-activated B (CD40-B) cells as sole antigen-presenting cells we successfully generated cyclin-A2 specific CTL from HLA-A*0201+ donors. Interestingly, high-avidity cyclin-A2 specific CTL lines, which recognized peptide-pulsed and antigen expressing target cells, were indeed generated by stimulation with CD40-B cells when pulsed with low concentrations of peptide, whereas CD40-B cells pulsed at saturating concentrations could only induce low-avidity CTL, which recognized peptide-pulsed target cells only. One high-avidity CTL line was subcloned and CTL clones, whose peptide concentration required for half-maximal lysis were less than 1 nM, could lyse cyclin-A2 expressing tumor cells. Taken together, cyclin A2 is an attractive candidate for immune intervention in a significant number of cancer patients and high-avidity T cells can be readily generated using CD40-B cells as antigen-presenting cells.

Original languageEnglish
Pages (from-to)2474-2478
Number of pages5
JournalInternational Journal of Cancer
Volume125
Issue number10
DOIs
Publication statusPublished - Nov 15 2009
Externally publishedYes

Fingerprint

Cyclin A2
Neoplasm Antigens
T-Lymphocytes
B-Lymphocytes
Peptides
Antigen-Presenting Cells
Neoplasms
Cyclin T
Allergy and Immunology
Immunotherapy
Epitopes
Cell Cycle
Clone Cells
Tissue Donors
Antigens

Keywords

  • CTL
  • Cyclin-A2
  • Immunotherapy
  • Tumor
  • Tumor antigen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kondo, E., Maecker, B., Draube, A., Klein-Gonzalez, N., Shimabukuro-Vornhagen, A., Schultze, J. L., & Von Bergwelt-Baildon, M. S. (2009). The shared tumor associated antigen cyclin-A2 is recognized by high-avidity T-cells. International Journal of Cancer, 125(10), 2474-2478. https://doi.org/10.1002/ijc.24629

The shared tumor associated antigen cyclin-A2 is recognized by high-avidity T-cells. / Kondo, Eisei; Maecker, Britta; Draube, Andreas; Klein-Gonzalez, Nela; Shimabukuro-Vornhagen, Alexander; Schultze, Joachim L.; Von Bergwelt-Baildon, Michael S.

In: International Journal of Cancer, Vol. 125, No. 10, 15.11.2009, p. 2474-2478.

Research output: Contribution to journalArticle

Kondo, E, Maecker, B, Draube, A, Klein-Gonzalez, N, Shimabukuro-Vornhagen, A, Schultze, JL & Von Bergwelt-Baildon, MS 2009, 'The shared tumor associated antigen cyclin-A2 is recognized by high-avidity T-cells', International Journal of Cancer, vol. 125, no. 10, pp. 2474-2478. https://doi.org/10.1002/ijc.24629
Kondo E, Maecker B, Draube A, Klein-Gonzalez N, Shimabukuro-Vornhagen A, Schultze JL et al. The shared tumor associated antigen cyclin-A2 is recognized by high-avidity T-cells. International Journal of Cancer. 2009 Nov 15;125(10):2474-2478. https://doi.org/10.1002/ijc.24629
Kondo, Eisei ; Maecker, Britta ; Draube, Andreas ; Klein-Gonzalez, Nela ; Shimabukuro-Vornhagen, Alexander ; Schultze, Joachim L. ; Von Bergwelt-Baildon, Michael S. / The shared tumor associated antigen cyclin-A2 is recognized by high-avidity T-cells. In: International Journal of Cancer. 2009 ; Vol. 125, No. 10. pp. 2474-2478.
@article{a9c0446b3e9d4b6e8247d32fcbea4d10,
title = "The shared tumor associated antigen cyclin-A2 is recognized by high-avidity T-cells",
abstract = "Cyclin-A2, a key cell cycle regulator, has been shown to be overexpressed in various types of malignancies with little expression in normal tissue. Such tumor-associated genes potentially are useful targets for cancer immunotherapy. However, high-avidity cyclin-specific T cells are considered to be thymically deleted. We identified at least one nonameric HLA-A*0201 binding cyclin-A2 epitope by a reverse immunology approach. Using a highly efficient T-cell expansion system that is based on CD40-activated B (CD40-B) cells as sole antigen-presenting cells we successfully generated cyclin-A2 specific CTL from HLA-A*0201+ donors. Interestingly, high-avidity cyclin-A2 specific CTL lines, which recognized peptide-pulsed and antigen expressing target cells, were indeed generated by stimulation with CD40-B cells when pulsed with low concentrations of peptide, whereas CD40-B cells pulsed at saturating concentrations could only induce low-avidity CTL, which recognized peptide-pulsed target cells only. One high-avidity CTL line was subcloned and CTL clones, whose peptide concentration required for half-maximal lysis were less than 1 nM, could lyse cyclin-A2 expressing tumor cells. Taken together, cyclin A2 is an attractive candidate for immune intervention in a significant number of cancer patients and high-avidity T cells can be readily generated using CD40-B cells as antigen-presenting cells.",
keywords = "CTL, Cyclin-A2, Immunotherapy, Tumor, Tumor antigen",
author = "Eisei Kondo and Britta Maecker and Andreas Draube and Nela Klein-Gonzalez and Alexander Shimabukuro-Vornhagen and Schultze, {Joachim L.} and {Von Bergwelt-Baildon}, {Michael S.}",
year = "2009",
month = "11",
day = "15",
doi = "10.1002/ijc.24629",
language = "English",
volume = "125",
pages = "2474--2478",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - The shared tumor associated antigen cyclin-A2 is recognized by high-avidity T-cells

AU - Kondo, Eisei

AU - Maecker, Britta

AU - Draube, Andreas

AU - Klein-Gonzalez, Nela

AU - Shimabukuro-Vornhagen, Alexander

AU - Schultze, Joachim L.

AU - Von Bergwelt-Baildon, Michael S.

PY - 2009/11/15

Y1 - 2009/11/15

N2 - Cyclin-A2, a key cell cycle regulator, has been shown to be overexpressed in various types of malignancies with little expression in normal tissue. Such tumor-associated genes potentially are useful targets for cancer immunotherapy. However, high-avidity cyclin-specific T cells are considered to be thymically deleted. We identified at least one nonameric HLA-A*0201 binding cyclin-A2 epitope by a reverse immunology approach. Using a highly efficient T-cell expansion system that is based on CD40-activated B (CD40-B) cells as sole antigen-presenting cells we successfully generated cyclin-A2 specific CTL from HLA-A*0201+ donors. Interestingly, high-avidity cyclin-A2 specific CTL lines, which recognized peptide-pulsed and antigen expressing target cells, were indeed generated by stimulation with CD40-B cells when pulsed with low concentrations of peptide, whereas CD40-B cells pulsed at saturating concentrations could only induce low-avidity CTL, which recognized peptide-pulsed target cells only. One high-avidity CTL line was subcloned and CTL clones, whose peptide concentration required for half-maximal lysis were less than 1 nM, could lyse cyclin-A2 expressing tumor cells. Taken together, cyclin A2 is an attractive candidate for immune intervention in a significant number of cancer patients and high-avidity T cells can be readily generated using CD40-B cells as antigen-presenting cells.

AB - Cyclin-A2, a key cell cycle regulator, has been shown to be overexpressed in various types of malignancies with little expression in normal tissue. Such tumor-associated genes potentially are useful targets for cancer immunotherapy. However, high-avidity cyclin-specific T cells are considered to be thymically deleted. We identified at least one nonameric HLA-A*0201 binding cyclin-A2 epitope by a reverse immunology approach. Using a highly efficient T-cell expansion system that is based on CD40-activated B (CD40-B) cells as sole antigen-presenting cells we successfully generated cyclin-A2 specific CTL from HLA-A*0201+ donors. Interestingly, high-avidity cyclin-A2 specific CTL lines, which recognized peptide-pulsed and antigen expressing target cells, were indeed generated by stimulation with CD40-B cells when pulsed with low concentrations of peptide, whereas CD40-B cells pulsed at saturating concentrations could only induce low-avidity CTL, which recognized peptide-pulsed target cells only. One high-avidity CTL line was subcloned and CTL clones, whose peptide concentration required for half-maximal lysis were less than 1 nM, could lyse cyclin-A2 expressing tumor cells. Taken together, cyclin A2 is an attractive candidate for immune intervention in a significant number of cancer patients and high-avidity T cells can be readily generated using CD40-B cells as antigen-presenting cells.

KW - CTL

KW - Cyclin-A2

KW - Immunotherapy

KW - Tumor

KW - Tumor antigen

UR - http://www.scopus.com/inward/record.url?scp=70349862891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349862891&partnerID=8YFLogxK

U2 - 10.1002/ijc.24629

DO - 10.1002/ijc.24629

M3 - Article

C2 - 19681121

AN - SCOPUS:70349862891

VL - 125

SP - 2474

EP - 2478

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 10

ER -